Abstract:Objective:To explore the efficacy and safety of intermittent infusion of ilaprazole sodium and high-dose continuous infusion of esomeprazole sodium in preventing rebleeding in patients with peptic ulcer bleeding after successful endoscopic hemostasis.Methods:This is a multi-center, interval randomized, double-blind, double-dummy, parallel controlled study. From March 3rd to June 15th, 2021, 151 patients with high risk of peptic ulcer bleeding and successfully underwent endoscopic hemostasis from 33 hospitals including the First Affiliated Hospital of Zhejiang University School of Medicine were enrolled. Patients were interval randomly divided into the trial group (74 cases) and the control group (77 cases). Patients in the trial group received intermittent intravenous infusion of ilaprazole sodium once daily (20 mg administered as a 60 min intravenous infusion on day 1, and 10 mg administered as a 30 min intravenous infusion on day 2 and 3); patients in the control group received continuous intravenous infusion of esomeprazole sodium for 72 h (esomeprazole sodium 80 mg at first dose in half an hour, and 8 mg per hour continuous intravenous infusion for 71.5 h). After intravenous infusion treatment, patients of both groups were given oral ilaprazole enteric-coated tablets, 10 mg each time, once a day for 4 d. The rebleeding rate after 72 h and within 7 d after treatment and the proportion of patients who received endoscopic retreatment or surgery due to rebleeding within 72 h after treatment were analysised based on the full analysis set (72 cases in the trial group and 75 cases in the control group); and the incidence rate of adverse reactions was observed in the two groups based on the safety analysis set (74 cases in the trial group and 76 cases in the control group). Chi-square test or Fisher exact probability test was used for statistical analysis.Results:There was no rebleeding case in the trial group within 72 h and 1 case of rebleeding within 7 d (1.39%, 1/72). In the control group, there was 1 case of rebleeding (1.33%, 1/75) within 72 h and 4 cases of rebleeding (5.33%, 4/75) within 7 d. There was no significant difference in rebleeding rate either after 72 h or within 7 d after treatment between the two groups (both P>0.05). Within 72 h of treatment, no patients in both groups needed endoscopic or surgical retreatment due to rebleeding. Adverse reactions occurred in 5 cases (6.8%, 5/74) and 6 cases (7.9%, 6/76) in the trial group and control group, respectively, which recovered spontaneously without treatment. No serious adverse reactions occurred in both groups. Conclusion:In patients with high-risk peptic ulcer bleeding with successful endoscopic hemostasis, intermittent intravenous infusion of ilaprazole sodium has similar efficacy and safety as continuous high-dose intravenous infusion of esomeprazole sodium, but the dosage of intermitten regimen is less, the administration is more convenient, and it is worthy of clinical promotion.

Clinical efficacy comparison of the different drug -combination treatments for non -steroidal anti-inflammatory drugs caused upper gastrointestinal hemorrage

Comparison of the Efficacy of Different Doses of Omeprazole for the Treatment of Non-varicose Upper Gastrointestinal Hemorrhage

The controlled study of efficacy and safety of infusion of ilaprazole sodium versus esomeprazole sodium in prevention of peptic ulcer rebleeding

EFFICACY OF INTRAVENOUS ADMINISTRATION OF OMEPRAZOLEIN THE TREATMENT OF UPPER GASTROINTESTINAL HEMORRHAGE CAUSED BY PEPTIC ULCER AND ACUTE GASTRIC MUCOSAL LESION

Analysis of the Cost-effectiveness of 2 Kinds Regimens in the Treatment of Brain Trauma and Cerebral Hem-orrhage Complicated with Upper Gastrointestinal Hemorrhage

The Prevention of Upper Gastrointestinal Bleeding in Seriously Ill Chinese Patients: A Randomised, Double-Blind Study Evaluating Esomeprazole Vs Cimetidine

Clinical Effect of High Dose Somatostatin, Omeprazole Combined with Hemostasis on the Acute Upper Gastrointestinal Bleeding Patients combined with Coagulation Dysfunction

Effect of Endoscopic Therapy and Omeprazole Injection on Patients with Active Bleeding Peptic Ulcer

Prevention of upper gastrointestinal bleeding in critically ill Chinese patients: a randomized, double-blind study evaluating esomeprazole and cimetidine

Effect of Intragastric Ph on Control of Peptic Ulcer Bleeding.

Efficacy of Esomeprazole in Combination with Levofloxacin and Amoxicillin in Treatment of Helicobacter Pylori-Associated Duodenal Ulcer

The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison.

Comparison of the effects of intravenous infusion of omeprazole and H2-receptor antagonists on intragastric pH in bleeding duodenal ulcer patients

Rabeprazole Sodium Injection in the Treatment of Non-Esophageal Variceal Upper Gastrointestinal Bleeding: a Randomized,blind and Positive Drug Parallel-Group Controlled Clinical Multicenter Study

Effects of Esomeprazole Combined with Trimebutine in Treatment for Non-Erosive Reflux Disease

Analysis of the effectiveness and effect-cost of different proton pump inhibitors (PPI) in the treatment of peptic ulcer bleeding

Comparison of octreotide,vasopressin, and omeprazole inpatients with acute bleeding portalhypertensive gastropathy: a controlled study

Observation on the Clinical Effect of Emergency Interventional Therapy on Acute Severe Non- Variceal Upper Gastrointestinal Bleeding

Efficacy of Emergency Endoscopic Hemostasis Combined with Somatostatin in Treatment of Upper Gastrointestinal Hemorrhage

Effect of omeprazole in treatment of peptic ulcer bleeding

Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study.